News: BDA BOD Australia secures binding letter of intent with a Swiss manufacturer, page-162

Bod has two different market opportunities within same segments.

1# Achieving a growth in existing beauty and skin care business
2# Maximize opportunities with swiss base Linnea for MM Products to include a unique medicinal skin care range plus a therapeutic product(s) in areas such as but not limited to nausea and vomiting, anti-inflammation, neuroprotection and anxiety disorders

However, implementing right strategy and achieving actual growth could take some time. But that's the reason BOD is actually trading less than $10m EV.

If BOD could increase revenue with existing business in coming months and get regulatory approval to Import and start clinical trails on future products produced by Linnea; then MC over $40-60m could be well achieved in coming months (in line with peers such as CPH, AC8 & MMJ). However, one step at a time and believe BOD management is slowly moving to the right direction.

cheers
J